

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/149925/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Garg, Amit, Dirr, McKenzie A., Jemec, Gregor B.E., Ingram, John R. , Schmitt, Jochen, Spuls, Phyllis and Alam, Murad 2022. Shifting focus from “what we do” to the “impact of what we do”: Application of outcome measures to routine clinical care in dermatology. *Journal of The American Academy of Dermatology* 87 , pp. 83-84.  
10.1016/j.jaad.2022.04.042

Publishers page: <http://dx.doi.org/10.1016/j.jaad.2022.04.042>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 **Article type:** Notes & Comments

2  
3 **Title:** Shifting Focus from ‘What we do’ to the ‘Impact of what we do’: application of outcome  
4 measures to routine clinical care in dermatology.

5  
6 Amit Garg, MD<sup>1</sup>, McKenzie A. Dirr, BA, BS<sup>2</sup>, Gregor B.E. Jemec MD, DMSc<sup>6,7</sup>, John R. Ingram<sup>8</sup>, DM,  
7 FRCP, Jochen Schmitt, MD, MPH<sup>9</sup>, Phyllis Spuls MD, PhD<sup>10</sup>, Murad Alam, MD, MSCI, MBA<sup>2-5</sup>

8  
9 **Affiliations:**

10 <sup>1</sup>Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra Northwell, New  
11 Hyde Park, New York.

12 <sup>2</sup>Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL

13 <sup>3</sup>Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL

14 <sup>4</sup>Department of Otolaryngology, Feinberg School of Medicine, Northwestern University, Chicago, IL

15 <sup>5</sup>Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University,  
16 Chicago, IL

17 <sup>6</sup>Department of Dermatology, Zealand University Hospital, Roskilde, Denmark

18 <sup>7</sup>Institute of Clinical Medicine, University of Copenhagen, Denmark

19 <sup>8</sup> Department of Dermatology, Division of Infection & Immunity, Cardiff University, Cardiff, UK

20 <sup>9</sup>Center for Evidence-Based Healthcare, Faculty of Medicine Carl Gustav Carus, Technische Universität  
21 Dresden, Dresden, Germany.

22 <sup>10</sup>Department of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam, the  
23 Netherlands.

24  
25 **Word count:** 494495

26 **Figure(s):** 0

27 **Table(s):** 0

28 **References:** 45

29  
30 **Corresponding Author:**

31 Amit Garg, MD

32 Donald and Barbara Zucker School of Medicine at Hofstra / Northwell

33 1991 Marcus Avenue, Suite 300

34 New Hyde Park, NY, 11042

35 Email: [amgarg@northwell.edu](mailto:amgarg@northwell.edu)

36  
37 **Authors:**

38 Amit Garg; [amgarg@northwell.edu](mailto:amgarg@northwell.edu), ORCID 0000-0003-0886-6856

39 McKenzie A. Dirr; [mckenzie.dirr@northwestern.edu](mailto:mckenzie.dirr@northwestern.edu)

40 Gregor B. E. Jemec; [gbj@regionsjaelland.dk](mailto:gbj@regionsjaelland.dk)

41 John R. Ingram; [ingramjr@cardiff.ac.uk](mailto:ingramjr@cardiff.ac.uk), ORCID 0000-0002-5257-1142

42 Jochen Schmitt; [jochen.schmitt@ukdd.de](mailto:jochen.schmitt@ukdd.de)

43 Phyllis Spuls; [ph.i.spuls@amsterdamumc.nl](mailto:ph.i.spuls@amsterdamumc.nl)

44 Murad Alam; [m-alam@northwestern.edu](mailto:m-alam@northwestern.edu)

45  
46 **Funding:** None

47 **Conflicts of Interest:** None

48 **Keywords:** dataderm, C3, CHORD, COUSIN, core outcome measurement instrument, outcome, quality,  
49 dermatology

50 To the Editor

51 The American Academy of Dermatology (AAD) in its capacity as a CMS-approved intermediary  
52 for the Merit-based Incentive Payment System (MIPS) has created a robust Qualified Clinical Data  
53 Registry (QCDR) in DataDerm.<sup>1</sup> However, MIPS measures are not intended to capture the ~~scope and~~  
54 breadth of dermatology practice, and many evaluate the process of practice, rather than its outcome. The  
55 QCDR component is therefore essential since it allows capture of specialty-specific measures that have  
56 more meaning to our patients, and consequently to the providers evaluating outcomes. Accordingly,  
57 DataDerm represents an important pragmatic service for dermatologists, and it offers potential for robust  
58 quality assessment, and by way of this, demonstration of value and identification of care gaps.

59 Requisite to quality assessment is having established measures to evaluate therapeutic outcomes.  
60 Our specialty is somewhat disadvantaged in that we have fewer validated measures or biomarkers specific  
61 to dermatologic disease that are also feasible to implement in practice. Diabetes has glycated hemoglobin,  
62 cardiovascular disease has blood pressure and lipid profile, and systemic lupus erythematosus has serum  
63 creatinine as indicators of disease severity. Given the dearth of established measures for skin conditions,  
64 our ability to assess outcomes, and therefore quality, in dermatology remains limited.

65 DataDerm captures much of ‘what we do’ (i.e., encounters, diagnoses, prescriptions). Practice  
66 and research communities in dermatology can also support its evolution towards comprehensively  
67 measuring the impact of what we do. Doing so will necessitate identification and development of well-  
68 functioning measures. Given the value of direct input from patients, patient reported outcomes (PROs),  
69 particularly for symptoms including as itch,<sup>2</sup> represent an important opportunity to measure this impact.  
70 In the absence of disease biomarkers, measuring impact should also include simple and efficient clinician  
71 reported outcomes (ClinROs) specifically designed for practice.

72 Several research organizations in dermatology are advancing development of dermatology-  
73 specific measures for clinical trials and routine practice. These groups identify useful measures and  
74 develop new ones when current measures are deemed inadequate. Among these organizations is C3, the  
75 CHORD COUSIN Collaboration, which includes nearly 20 research groups each focusing on a different

76 skin condition, including acne, skin cancers, facial aging, vitiligo, hand eczema, pustular psoriasis,  
77 pyoderma gangrenosum, vascular malformations, pressure ulcers, and others.<sup>2</sup> Already there has been  
78 significant advancement in the development of outcome measures for atopic dermatitis and hidradenitis  
79 suppurativa, by C3 member groups HOME and HiSTORIC, respectively.<sup>2-43-5</sup>

80         The success of DataDerm will also require the commitment from community and academic  
81 practices in dermatology to implement these measures, along with the innovation to overcome barriers  
82 such as time and infrastructure. Meaningful engagement by dermatologists will ensure robust and  
83 generalizable data inclusive of sufficient heterogeneity in demographics, contextual characteristics,  
84 disease, disease activity, and treatments.

85         DataDerm has pioneered the process of collecting clinical data from dermatologists, and this has  
86 also enabled dermatologists to demonstrate compliance with CMS-mandated quality measures. Measuring  
87 quality of care will ultimately necessitate collective alignment from the profession, the organization, and  
88 research community in dermatology. The 2021 DataDerm update indicates we are well on our way.<sup>1</sup>

89 **References**

- 90 1. Van Beek MJ, Swerlick RA, Mathes B, et al. The 2021 annual report of DataDerm: The database  
91 of the American Academy of Dermatology [published online ahead of print, 2021 Nov 24]. *J Am*  
92 *Acad Dermatol.* 2021;S0190-9622(21)02896-6. doi:10.1016/j.jaad.2021.11.029
- 93 2. Erickson S, Kim BS. Research Techniques Made Simple: Itch Measurement in Clinical Trials. J  
94 Invest Dermatol. 2019;139(2):264-269.
- 95 2.3. CHORD COUSIN Collaboration. Available at: <http://cs-cousin.org>. Accessed April 25, 2022.
- 96 3.4. Williams HC, Schmitt J, Thomas KS, Spuls PI, Simpson EL, Apfelbacher CJ, Chalmers JR,  
97 Furue M, Katoh N, Gerbens LA, Leshem YA, Howells L, Singh JA, Boers M; HOME Initiative.  
98 The HOME Core outcome set for clinical trials of atopic dermatitis. *J Allergy Clin Immunol.*  
99 2022 Mar 26;S0091-6749(22)00389-X. doi: 10.1016/j.jaci.2022.03.017.
- 100 4.5. Thorlacius L, Ingram JR, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola JF, Dellavalle  
101 R, Nielsen SM, Christensen R, Garg A and Jemec GBE, on behalf of the Hidradenitis  
102 Suppurativa Core Outcomes Set International Collaboration (HiSTORIC). A Core Domain Set  
103 For Hidradenitis Suppurativa Trial Outcomes: An International Delphi Process. *Br J Dermatol.*  
104 2018;179(3):642-650..